Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07300982 · ClinicalTrials.gov registry record · Phase 1
Studies of Insulin and Glucagon Action in the Liver
A Phase 1 study, sponsored by Duke University.
- Not yet
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
NCT07300982 is a Phase 1 study that has not yet begun recruiting, run by Duke University. The registered enrollment target is 40 participants.
The verdict
NCT07300982, a Phase 1 study, has not yet begun recruiting, sponsored by Duke University.
- NOT YET RECRUITING
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
Study Summary
This study examines how glucagon works to regulate glucose metabolism, based on new findings that suggest glucagon signaling in the liver has more than one role, and that these multiple roles can be opposing in nature. Understanding this biology provides an opportunity to develop new generations of glucagon-based drugs that target specific pathways, making them more effective at controlling blood glucose. Participants will complete paired, 5-hour hyperinsulinemic glucose clamp visits in which they receive either glucagon or saline infusions while blood glucose is maintained and frequent blood samples are collected. The primary focus is whether coordinated glucagon and insulin signaling enhances hepatic insulin sensitivity.
Interventions
- DRUG Saline (placebo)
- DRUG Glucagon
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2026-04 |
| Est. Completion | 2029-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07300982
The ClinicalTrials.gov registry entry for NCT07300982 describes a study currently listed as not yet recruiting, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Duke University, which has 1,725 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Saline (placebo) is the first listed.
NCT07300982 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07300982 about?
NCT07300982 is a clinical study titled "Studies of Insulin and Glucagon Action in the Liver". This study examines how glucagon works to regulate glucose metabolism, based on new findings that suggest glucagon signaling in the liver has more than one role, and that these multiple roles can be opposing in nature. Understanding this biology provides an opportunity to develop new generations of ...
What is the current status of trial NCT07300982?
This trial is currently not yet recruiting. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2026-04. Estimated completion is 2029-12.
What interventions are being tested in trial NCT07300982?
The interventions under investigation include: Saline (placebo) (DRUG), Glucagon (DRUG).
Who is sponsoring clinical trial NCT07300982?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.